Skip to content

英莫德

US · INMD #3410 按市值排名 上市于 2019
14.16 -0.16 -1.12%
实时 - 追踪5344个代码 - 心跳于92秒前 · 2026-10-16 19:30

✦ 量化合理价值 计算方式说明

接近合理价值
6.68 合理价值 ≈ 19.77 32.85
  • 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为6.68-32.85。
  • 当前价格比按平均倍数计算的合理价值(19.77)低28.4%。

估值 各估值倍数与自身5年区间的对比

市净率 1.28 低于历史水平 第3百分位
5年平均 3.90 · 在Medical Devices中排名第33/125
市盈率 11.58 处于历史正常水平 第57百分位
5年平均 13.82 · 前瞻 12.30 · 在Medical Devices中排名第4/38
市销率 2.15 低于历史水平 第1百分位
5年平均 5.11 · 前瞻 2.18 · 在Medical Devices中排名第56/136

同业对比 Medical Devices

公司 市值 市盈率(TTM) 市净率 股息率
英莫德 (INMD) 814.83M 11.70 1.29 0.00%
Abbott Laboratories (ABT) 181.50B 33.94 3.55 2.33%
Medtronic (MDT) 121.20B 23.34 2.41 3.01%
Stryker Corp (SYK) 113.02B 30.53 4.71 1.18%
Boston Scientific (BSX) 64.33B 17.97 2.58 0.00%
Edwards Lifesciences (EW) 49.92B 50.35 4.70 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★☆ 合理价值15.47 经济护城河None 不确定性Medium

当前股价低于晨星合理价值估算9.2%。

合理价值

InMode Ltd is assigned a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 9% discount to our quantitative fair value estimate of $15.47 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The company's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 77.6% sits in the top 40% globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are cheap.

The company's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 10.1%, a core component of profitability, ranks in the top 20% compared with global peers. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

经济护城河

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

英莫德 讨论区 0 条评论

发表评论